Skip to main content
. 2020 Jul 7;136(15):1760–1772. doi: 10.1182/blood.2020005230

Figure 2.

Figure 2.

miR-125a-5p regulates MK PPF. (A-F) LNAs were used to inhibit miR-125a-5p (“125a LNA” throughout figure). (A) Fold change of miR-125a-5p compared with control after LNA inhibition (n = 6). (B-D) Flow cytometric analysis of the effect of miR-125a-5p inhibition on (B) HSCs, (C) HSPCs, and (D) mature MKs at days 0, 3, 6, 9, and 13 (n = 3). (E) Representative brightfield images of MKs with PPs (arrows) after miR-125a-5p inhibition. Scale bar, 50 μm. (F) Plot of percentages of day 13 cells with PPs after treatment with LNA inhibitors, scored blinded as to the treatment group (n = 6). (G) Plot of percentages of day 13 cells with PPs after transduction with miR-125a-5p overexpressing lentivirus. conL lenti, a mutated sequence of miR-125a-5p lentiviral plasmid used for transduction assays as a negative control (n = 6); negC LNA, negative LNA control; n.s., not significant.